What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Alberta Hoi alberta_hoi
3 years 6 months ago
I also wonder about the significance of Ro52. Some of the commonly observed features like gastrointestinal dysmotility are not captured. https://t.co/UPljYf65vH
EnvisionRheumat ERheumat
3 years 6 months ago
#EULAR2022
How to Manage (HOT): Lupus Nephritis
Voclosporin is the new CNI
long term reno-ischemic effects need to be looked at https://t.co/8RqayemaRu
EnvisionRheumat ERheumat
3 years 6 months ago
#EULAR2022
WIN session
Sarcoidosis – an update for rheumatologists
Clinical Approach https://t.co/AYOEDsnDZ6
Rheum Cat rheum_cat
3 years 6 months ago
#EULAR2022 COVID orals
OP0172
Swedish COVID19-Reuma registry with n=414 ARD + 61 controls
RTX n=145, ABA n=21
In MVA, use of RTX, ABA were a/w lower Ab response. We've known this about RTX; growing data for ABA as well? https://t.co/Es9bA54m8E
Elena Joerns EJoerns
3 years 6 months ago
Excited to share our recent work "IPAF: What the Rheumatologist Needs to Know."
@jeffsparks @UnaMakris @DrDavidKarp @UTSW_LungLadies @UTSWRheum https://t.co/O0BsrRyHx8 https://t.co/R3lQMGFgUb
Kunal Chandwar kunalchandwar
3 years 6 months ago
🔥Hot off the press🔥
🆕Our Comments on various GC protocols in @IJRheum
The changing paradigm of glucocorticoid therapy in antineutrophil cytoplasmic antibody-associated vasculitis
https://t.co/4BjfkvPVAY https://t.co/gMXg7qQJWY
Dr. Rachel Tate uptoTate
3 years 6 months ago
"Implementation (of guidelines) is key but remains the weakest part of the process" Dr. @DanielAletaha #EULAR2022 @RheumNow https://t.co/9ULIAA7dvg
Christian Ammitzbøll RheumTweeter
3 years 6 months ago
Easy clinical tool for predicting lymphoma development at the time of #Sjogrens syndrome #EULAR2022 https://t.co/tQ6B0iVRnb
Richard Conway RichardPAConway
3 years 6 months ago
Dr Buch. ORAL Surveillance. MACE, VTE, Malignancy all more common in those with high (>20%) baseline CV risk or history CAD. HRs 1-2 for most but for VTE and high baseline CV risk, HR 6-11! @RheumNow #EULAR2022 POS0237 https://t.co/9DI4KotyOp
ARD & RMD Open ARD_BMJ
3 years 6 months ago
Dr Elena Nikiphorou explaining how the Western diet can bring on and worsen inflammation joint disease symptoms. We should look to include more Omega 3 than Omega 6 in our diets #EULAR2022
PB https://t.co/nIKOSDPURU
Ashima Makol MD AshimaMakol
3 years 6 months ago
A very comprehensive overview of progress in the understanding of #IIM pathogenetic mechanisms outlining the role of
👉 Type 1 INF pathway
👉 Vasculopathy
👉 NETs
👉 Mitochondrial Dysfunction
#EULAR2022
Dr. Lisa Rider https://t.co/BXbXlYTHYM
Richard Conway RichardPAConway
3 years 6 months ago
van Dijk et al. MTP squeeze positivity is caused by both MTP synovitis (OR 3.2 (1.4–7.2) and intermetatarsal bursitis (OR 3.9 (1.7–8.8)). If + MTP squeeze - 10% synovitis, 15% IMB and 13% both @RheumNow #EULAR2022 OP0290 https://t.co/eVSU4i8gBK
David Liew drdavidliew
3 years 6 months ago
Robert Landewe isn't lying down.
"I am chatting to my artificial intelligence doctor in the United States. I am asking him why I had a headache in the last talk"
He worries telehealth reverts to box checking, & we're not ready to drop thinking from medicine #EULAR2022 @RheumNow https://t.co/ApBS4T4Wpc
ARD & RMD Open ARD_BMJ
3 years 6 months ago
CAR-T cell treatment of refractory systemic #lupus
Biological results
#SLE
#EULAR2022
>CR https://t.co/JK4lsWcn2c
Poster Hall